Outpost Medicine is a biopharmaceutical company
At Outpost, they are committed to developing novel therapeutics for the treatment of gastrointestinal and urologic disorders. The company's lead clinical-stage product candidate is in development for the treatment of overactive bladder (OAB) and irritable bowel syndrome (IBS).
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Mar 14, 2016 | Series A | $41M | 1 | — | — | Detail |